Page 228 - 2021_12-Haematologica-web

Case Report
expanding the clinical phenotype. Rheumatol Oxf Engl. 2021;60(9):
e321-e323.
4. Osio A, Battistella M, Feugeas J-P, et al. Myelodysplasia cutis versus
leukemia cutis. J Invest Dermatol. 2015;135(9):2321-2324.
5. Lee SMS, Fan BE, Lim JH-L, Goh LL, Lee JSS, Koh LW. A case of VEXAS syndrome manifesting as Kikuchi-Fujimoto disease, relaps- ing polychondritis, venous thromboembolism and macrocytic
anaemia. Rheumatol Oxf Engl. 2021;60(9):e304-e306.
6. Poulter JA, Collins JC, Cargo C, et al. Novel somatic mutations in UBA1 as a cause of VEXAS syndrome. Blood. 2021;137(26):3676-
3681.
7. Ghoufi L, Ortonne N, Ingen-Housz-Oro S, et al. Histiocytoid Sweet
syndrome is more frequently associated with myelodysplastic syn- dromes than the classical neutrophilic variant: a comparative series of 62 patients. Medicine (Baltimore). 2016;95(15):e3033.
8.Verger E, Cassinat B, Chauveau A, et al. Clinical and molecular response to interferon-α therapy in essential thrombocythemia
patients with CALR mutations. Blood. 2015;126(24):2585-2591.
9. Rampal R, Ahn J, Abdel-Wahab O, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neo-
plasms. Proc Natl Acad Sci U S A. 2014;111(50):E5401-E5410.
10. Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignan- cies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;
15(3):333-342.
11. Jones JR, Cairns DA, Gregory WM, et al. Second malignancies in the
context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016; 6(12):e506.
12. Kiladjian J-J, Rain J-D, Bernard J-F, Briere J, Chomienne C, Fenaux P. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in poly- cythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32(4):417-421.
3248
haematologica | 2021; 106(12)